FCM
EGRX

Farallon Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Farallon Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-100,000
Closed -$1.26M – 99
2014
Q3 		$1.26M Hold
100,000
– – 0.02% 79
2014
Q2 		$1.43M Hold
100,000
– – 0.02% 91
2014
Q1 		$1.27M Buy
+100,000
New +$1.36M 0.03% 80

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
GE
General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Farallon Capital Management's EGRX Position: Q4 2014 in Review

Farallon Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2014, closing a stake of 100,000 shares — an estimated $1.26M sold.

Farallon Capital Management first reported a position in EGRX in Q1 2014 and held it in 3 quarters. The position peaked at $1.43M in Q2 2014. 28 funds tracked by Wall St. Rank hold EGRX as of Q4 2014.

  • Farallon Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Farallon Capital Management sold 100,000 Eagle Pharmaceuticals, Inc. shares in Q4 2014, an estimated $1.26M.
  • Farallon Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 3 quarters.
  • Farallon Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $1.43M in Q2 2014.
  • 28 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2014.

Based on Farallon Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.